Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy

Cancer Biology and Medicine

Volumn 10, Issue 3, 2013, Pages 158-164

  Ke, Yang ^a   Ma, Liang ^a   You, Xue Mei ^a   Huang, Sheng Xin ^a   Liang, Yong Rong ^a   Xiang, Bang De ^a   Li, Le Qun ^a   Zhong, Jian Hong ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Antiviral therapy; Hepatocellular carcinoma; Propensity score matching; Recurrence free survival rate

Indexed keywords

LAMIVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 84891288949     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2013.03.006     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Zhong J H, Mo X S, Xiang B D, Yuan W P, Jiang J F, Xie G S, et al. Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. PLoS One 2013;8:e58082.
3. Zhong J H, Li H, Li L Q, You X M, Zhang Y, Zhao Y N, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol 2012;38:286-295.
4. Zhong J H, Ma L, Wu L C, Zhao W, Yuan W P, Wu F X, et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract 2012;66:21-27.
5. Zhong J H, Li le Q, Wu L C. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. Cochrane Database Syst Rev 2011;(12):CD008713.
6. Zhong J H, Li L Q. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. Hepatol Res 2010;40:943-953.
7. Forner A, Llovet J M, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
8. Ministry of Health of the People's Republic of China. Diagnosis management and treatment of hepatocellular carcinoma (2011 Version). J Clin Hepatol 2011;27:1141-1159.
9. Wu C Y, Chen Y J, Ho H J, Hsu Y C, Kuo K N, Wu M S, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906-1914.
10. Chan A C, Chok K S, Yuen W K, Chan S C, Poon R T, Lo C M, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 2011;146:675-681.
11. Piao C Y, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort. Acta Med Okayama 2005;59:217-224.
12. Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22:1929-1935.
13. Wong J S, Wong G L, Tsoi K K, Wong V W, Cheung S Y, Chong C N, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011;33:1104-1112.
14. Zhong J H, Xiang B D, Gong W F, Ke Y, Mo Q G, Ma L, et al. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One 2013;8:e68193.
15. Zhong J H, Ke Y, Gong W F, Xiang B D, Ma L, Ye X P, et al. Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma. Ann Surg 2013. [Epub ahead of print].
16. Jia J D, Li L J. The guideline of prevention and treatment for chronic hepatitis B. J Clin Hepatol 2011;27:113-128.
17. Shaikh T, Cooper C. Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis. Can J Gastroenterol 2012;26:148-150.
18. Li N, Lai E C, Shi J, Guo W X, Xue J, Huang B, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 2010;17:179-185.
19. Koda M, Nagahara T, Matono T, Suqihara T, Mandai M, Ueki M, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med 2009;48:11-17.
20. Li L Q, Peng T, Lin J L, Wu S, Liang S T, Lu Y F, et al. The Impact of Cell Source of Recurrent Hepatic Carcinoma on Time of Recurrence. Chin J Clin Oncol 2000;27:635-636.
21. Liaw Y F, Sung J J, Chow W C, Farrell G, Lee C Z, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
22. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005;32:173-184.
23. Yang T, Lu J H, Zhai J, Lin C, Yang G S, Zhao R H, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol 2012;38:683-691.
24. Cheung Y S, Chan H L, Wong J, Lee K F, Poon T C, Wong N, et al. Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. Asian J Surg 2008;31:41-49.
25. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis b virus-related hepatocellular Carcinoma: A two-stage longitudinal clinical study. J Clin Oncol 2013;31:3647-3655.